Document:

EX-10.3

 Exhibit 10.3 

THE SECURITIES REPRESENTED BY THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AND HAVE BEEN ACQUIRED FOR INVESTMENT
AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH SALE OR DISTRIBUTION MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL IN A FORM SATISFACTORY TO THE COMPANY
THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE SECURITIES ACT OF 1933. 
  

			
	     Warrant No. NVCW –
[            ]
	 	Date of Issuance: December [    ], 2022

 Number of Shares:
[                    ] 
 (subject to
adjustment) 
 KINETA, INC. 

STOCK PURCHASE WARRANT 

Kineta, Inc., a Washington corporation (the “Company”), for value received, hereby certifies that
[                    ], or its registered assigns (the “Registered Holder”), is entitled, subject to the terms set forth below, to
purchase from the Company, at any time on or after the Closing Date (subject to the conditions set forth in Section 1 below) and on or before the Expiration Date (each, as defined below) shares of the Company’s Non-Voting Common Stock at a price per share of $0.01. The shares purchasable upon exercise of this Warrant, and the purchase price per share, as adjusted from time to time pursuant to the provisions of this
Warrant, are hereinafter referred to as the “Warrant Stock” and the “Purchase Price”, respectively. 

1.    Number of Shares. Commencing on the Closing Date (as defined in that certain Securities
Purchase Agreement by and among Yumanity Therapeutics, Inc., a Delaware corporation (“Yumanity”) and the purchaser parties thereto, dated as of June 5, 2022, as amended by (i) that certain Amendment No. 1 to
Securities Purchase Agreement dated October 24, 2022, and (ii) that certain Amendment No. 2 to Securities Purchase Agreement of even date hereof (as may be further amended and/or restated from time to time, the “PIPE
Agreement”)) upon the occurrence of the First Tranche Closing (as defined in the PIPE Agreement) pursuant to which, for the avoidance of doubt, the undersigned Registered Holder purchases all of the First Tranche Shares (as defined in the
PIPE Agreement) allocated to it in accordance with the terms and conditions of the PIPE Agreement, and, subject to the terms and conditions hereinafter set forth, the Registered Holder is entitled, upon surrender of this Warrant, to purchase from
the Company the number of shares (subject to adjustment as provided herein) of Warrant Stock first set forth above. 

2.    Acknowledgement and Consent to Assumption. The Company and the undersigned Registered Holder
hereby acknowledge and agree that, in accordance with Section 5.5(a)(iv) of the Merger Agreement (as defined in the PIPE Agreement), this Warrant shall be converted into and become a warrant to purchase shares of Yumanity Common Stock (as
defined in the Merger Agreement) and Yumanity shall assume this Warrant in accordance with its terms, effective as of the Effective Time (as defined in the Merger Agreement). The Registered Holder hereby irrevocably waives and forever discharges any
rights under this Warrant to receive advance written notice of the Company’s execution of the Merger Agreement or the performance by the Company of any of the transactions contemplated by the Merger Agreement. The Registered Holder hereby
irrevocably consents to the adoption of this Warrant by Yumanity in accordance with the terms of the Merger Agreement, contingent and effective upon the Effective time. In connection with the closing of the Merger (as defined in the Merger
Agreement) and the assumption of this Warrant by Yumanity, the Registered Holder hereby agrees to execute and deliver to the Company and Yumanity all transaction documents related to the assumption of this Warrant, including an amended form of
warrant and other ancillary agreements, with customary representations and warranties and transfer restrictions applicable to all holders of warrants issued on substantially similar terms. The Warrants and Warrant Stock will not be subject to the
terms of any lock-up or similar agreement to which the Registered Holder is otherwise subject, nor will the Warrants or Warrant Stock be subject to any similar restrictions on transfer to be imposed by the
Company’s or Yumanity’s bylaws. 

 3.    Exercise. 

(a)    Manner of Exercise. This Warrant may be exercised by the Registered Holder, in whole or in
part, by surrendering this Warrant, with the purchase/exercise form appended hereto as Exhibit A duly executed by such Registered Holder or by such Registered Holder’s duly authorized attorney, at the principal office
of the Company, or at such other office or agency as the Company may designate, accompanied by payment in full of the Purchase Price payable in respect of the number of shares of Warrant Stock purchased upon such exercise. The Purchase Price may be
paid by cash, check, wire transfer, or by the surrender of promissory notes or other instruments representing indebtedness of the Company to the Registered Holder. 

(b)    Effective Time of Exercise. Each exercise of this Warrant shall be deemed to have been
effected immediately prior to the close of business on the day on which this Warrant shall have been surrendered to the Company as provided in Section 3(a). At such time, the person or persons in whose name or names any notices of issuance for
Warrant Stock shall be issuable upon such exercise as provided in Section 3(d) shall be deemed to have become the holder or holders of record of the Warrant Stock referred to in such notices of issuance. 

(c)    Net Issue Exercise. 

(i)    In lieu of exercising this Warrant in the manner provided in Section 3(a), the Registered Holder may elect to
receive shares equal to the value of this Warrant (or the portion thereof being canceled) by surrender of this Warrant at the principal office of the Company together with notice of such election on the purchase/exercise form appended hereto as
Exhibit A duly executed by such Registered Holder or such Registered Holder’s duly authorized attorney, in which event the Company shall issue to such Registered Holder a number of shares of Warrant Stock computed
using the following formula: 
  

									
		 	 X =
	  	Y (A - B)	  		  	
	 	 	 	  	A	  	 	  	 

  
 -2- 

					
	Where	  	X =	  	The number of shares of Warrant Stock to be issued to the Registered Holder.
			
		  	Y =	  	The number of shares of Warrant Stock purchasable under this Warrant (at the date of such calculation).
			
		  	A =	  	The fair market value of one share of Warrant Stock (at the date of such calculation).
			
		  	B =	  	The Purchase Price (as adjusted to the date of such calculation).

 (ii)    For purposes of this Section 3(c), the fair market value of Warrant Stock on
the date of calculation shall mean with respect to each share of Warrant Stock: 
 (A)    if the exercise is in
connection with an initial public offering of the Company’s Common Stock, and if the Company’s Registration Statement relating to such public offering has been declared effective by the Securities and Exchange Commission, then the fair
market value shall be the initial “Price to Public” per share specified in the final prospectus with respect to the offering; 

(B)    if this Warrant is exercised after, and not in connection with, the Company’s initial public offering, and if
the Company’s Common Stock is traded on a securities exchange or actively traded over-the-counter: 

(1)    if the Company’s Common Stock is traded on a securities exchange, the fair market value shall be deemed to be
the average of the closing prices over a thirty (30) day period ending three days before date of calculation; or 

(2)    if the Company’s Common Stock is actively traded over-the-counter, the fair market value shall be deemed to be the average of the closing bid or sales price (whichever is applicable) over the thirty (30) day period ending three days before the date of
calculation; or 
 (C)    if neither (A) nor (B) is applicable, the fair market value of Warrant Stock shall be at
the highest price per share which the Company could obtain on the date of calculation from a willing buyer (not a current employee or director) for shares of Warrant Stock sold by the Company, from authorized but unissued shares, as determined in
good faith by the Board of Directors, unless the Company is at such time subject to an acquisition as described in Section 7(b), in which case the fair market value of Warrant Stock shall be deemed to be the value received by the holders of
such stock pursuant to such acquisition. 
 (d)    Delivery to Holder. As soon as practicable after
the exercise of this Warrant in whole or in part, and in any event within ten (10) days thereafter, the Company at its expense will cause to be issued in the name of, and delivered to, the Registered Holder, or as such Holder (upon payment by
such Holder of any applicable transfer taxes) may direct: 
 (i)    a notice or notices of issuance for the number of
shares of Warrant Stock to which such Registered Holder shall be entitled, and 

  
 -3- 

 (ii)    in case such exercise is in part only, a new warrant or
warrants (dated the date hereof) of like tenor, calling in the aggregate on the face or faces thereof for the number of shares of Warrant Stock equal (without giving effect to any adjustment therein) to the number of such shares called for on the
face of this Warrant minus the number of such shares purchased by the Registered Holder upon such exercise as provided in Sections 3(a) or 3(c). 

4.    Adjustments. 

(a)    Stock Splits and Dividends. If the Company’s outstanding shares of the same class as the
Warrant Stock shall be subdivided into a greater number of shares or a dividend in the Company’s shares of the same class as the Warrant Stock shall be paid in respect of the Company’s shares of the same class as the Warrant Stock, the
Purchase Price in effect immediately prior to such subdivision or at the record date of such dividend shall simultaneously with the effectiveness of such subdivision or immediately after the record date of such dividend be proportionately reduced.
If the Company’s outstanding shares of the same class as the Warrant Stock shall be combined into a smaller number of shares, the Purchase Price in effect immediately prior to such combination shall, simultaneously with the effectiveness of
such combination, be proportionately increased. When any adjustment is required to be made in the Purchase Price, the number of shares of Warrant Stock purchasable upon the exercise of this Warrant shall be changed to the number determined by
dividing (i) an amount equal to the number of shares issuable upon the exercise of this Warrant immediately prior to such adjustment, multiplied by the Purchase Price in effect immediately prior to such adjustment, by (ii) the Purchase
Price in effect immediately after such adjustment. 
 (b)    Reclassification, Etc. In case there
occurs any reclassification or change of the outstanding securities of the Company or of any reorganization of the Company (or any other corporation the stock or securities of which are at the time receivable upon the exercise of this Warrant) or
any similar corporate reorganization on or after the date hereof, then and in each such case the Registered Holder, upon the exercise hereof at any time after the consummation of such reclassification, change, or reorganization shall
be entitled to receive, in lieu of the stock or other securities and property receivable upon the exercise hereof prior to such consummation, the stock or other securities or property to which such Holder would have been entitled upon such
consummation if such Holder had exercised this Warrant immediately prior thereto, all subject to further adjustment pursuant to the provisions of this Section 4. 

(c)    Adjustment Certificate. When any adjustment is required to be made in the Warrant Stock or the
Purchase Price pursuant to this Section 4, the Company shall promptly mail to the Registered Holder a certificate setting forth (i) a brief statement of the facts requiring such adjustment, (ii) the Purchase Price after such
adjustment and (iii) the kind and amount of stock or other securities or property into which this Warrant shall be exercisable after such adjustment. 

5.    Transfers. 

(a)    Unregistered Security. Each holder of this Warrant acknowledges that none of the Company’s
securities (including this Warrant and the Warrant Stock) have been registered under the Securities Act of 1933, as amended (the “Securities Act”), and agrees not to 

  
 -4- 

 
sell, pledge, distribute, offer for sale, transfer or otherwise dispose of this Warrant or any Warrant Stock issued upon its exercise (or any securities issued by the Company upon conversion or
exchange thereof) in the absence of (i) an effective registration statement under the Securities Act as to the sale of any such securities and registration or qualification of such securities under any applicable U.S. federal or state
securities law then in effect, or (ii) an opinion of counsel, satisfactory to the Company, that such registration and qualification are not required. Each notice of issuance with respect to Warrant Stock issued upon the exercise of this Warrant
(and any securities issued by the Company upon conversion or exchange thereof) shall bear a legend substantially to the foregoing effect. 

(b)    Transferability. Subject to the provisions of Section 5(a) hereof, this Warrant and all
rights hereunder are transferable, in whole or in part, upon surrender of the Warrant with a properly executed assignment (in the form of Exhibit B hereto) at the principal office of the Company. 

(c)    Warrant Register. The Company will maintain a register containing the names and addresses of
the Registered Holders of this Warrant. Until any transfer of this Warrant is made in the warrant register, the Company may treat the Registered Holder of this Warrant as the absolute owner hereof for all purposes; provided, however,
that if this Warrant is properly assigned in blank, the Company may (but shall not be required to) treat the bearer hereof as the absolute owner hereof for all purposes, notwithstanding any notice to the contrary. Any Registered Holder may change
such Registered Holder’s address as shown on the warrant register by written notice to the Company requesting such change. 

6.    Termination. This Warrant (and the right to purchase securities upon exercise hereof) shall
terminate upon the earliest to occur of the following (the “Expiration Date”): 
 (a)    the 36 month
anniversary of the date of issuance first set forth above; 
 (b)    the sale, conveyance or disposal of all or
substantially all of the Company’s property or business or any transaction or series of related transactions in which more than fifty percent (50%) of the voting securities of the Company is disposed of, provided that this
Section 6(b) shall not apply to (x) a merger effected exclusively for the purpose of changing the domicile of the Company or to an equity financing in which the Company is the surviving corporation or (y) the Merger (as defined in the
Merger Agreement); or 
 (c)    the termination of the PIPE Agreement in accordance with its terms prior to the First
Tranche Closing. 
 7.    Notices of Certain Transactions. In case: 

(a)    the Company shall take a record of the holders of its outstanding stock of the same class as the Warrant Stock (or
other stock or securities at the time deliverable upon the exercise of this Warrant) for the purpose of entitling or enabling them to receive any dividend or other distribution, or to receive any right to subscribe for or purchase any shares of
stock of any class or any other securities, or to receive any other right, 

  
 -5- 

 (b)    of any capital reorganization of the Company, any
reclassification of the capital stock of the Company, any consolidation or merger of the Company, any consolidation or merger of the Company with or into another corporation (other than a consolidation or merger in which the Company is the surviving
entity), or any transfer of all or substantially all of the assets of the Company, or 
 (c)    of the voluntary or
involuntary dissolution, liquidation or winding-up of the Company, 
 then, and in each such case, the Company will
mail or cause to be mailed to the Registered Holder of this Warrant a notice specifying, as the case may be, (i) the date on which a record is to be taken for the purpose of such dividend, distribution or right, and stating the amount and
character of such dividend, distribution or right, or (ii) the effective date on which such reorganization, reclassification, consolidation, merger, transfer, dissolution, liquidation, winding-up,
redemption or conversion is to take place, and the time, if any is to be fixed, as of which the holders of record of the Company’s outstanding stock of the same class as the Warrant Stock (or such other stock or securities at the time
deliverable upon such reorganization, reclassification, consolidation, merger, transfer, dissolution, liquidation, winding-up, redemption or conversion) are to be determined. Such notice shall be mailed at
least ten (10) days prior to the record date or effective date for the event specified in such notice. 

8.    Reservation of Stock. The Company will at all times reserve and keep available, solely for the
issuance and delivery upon the exercise of this Warrant, such shares of Warrant Stock and other stock, securities and property, as from time to time shall be issuable upon the exercise of this Warrant. 

9.    Exchange of Warrants. Upon the surrender by the Registered Holder of any Warrant or Warrants,
properly endorsed, to the Company at the principal office of the Company, the Company will issue and deliver to or upon the order of such Registered Holder, at the Company’s expense, a new Warrant or Warrants of like tenor, in the name of such
Registered Holder or as such Registered Holder (upon payment by such Registered Holder of any applicable transfer taxes) may direct, calling in the aggregate on the face or faces thereof for the number of shares of Warrant Stock called for on the
face or faces of the Warrant or Warrants so surrendered. 
 10.    Replacement of Warrants. Upon
receipt of evidence reasonably satisfactory to the Company of the loss, theft, destruction or mutilation of this Warrant and (in the case of loss, theft or destruction) upon delivery of an indemnity agreement (with surety if reasonably required) in
an amount reasonably satisfactory to the Company, or (in the case of mutilation) upon surrender and cancellation of this Warrant, the Company will issue, in lieu thereof, a new Warrant of like tenor. 

11.    No Rights as Stockholder. Until the exercise of this Warrant, the Registered Holder of this
Warrant shall not have or exercise any rights by virtue hereof as a stockholder of the Company. 

  
 -6- 

 12.    No Fractional Shares. No fractional shares
of Warrant Stock will be issued in connection with any exercise hereunder. In lieu of any fractional shares which would otherwise be issuable, the Company shall pay cash equal to the product of such fraction multiplied by the fair market value of
one share of Warrant Stock on the date of exercise, as determined in good faith by the Company’s Board of Directors. 

13.    Attorney’s Fees. If any action at law or in equity (including arbitration) is necessary
to enforce or interpret the terms of any of this Warrant, the prevailing party shall be entitled to reasonable attorney’s fees, costs and necessary disbursements in addition to any other relief to which such party may be entitled. 

14.    Representations and Warranties of Registered Holder. The Registered Holder represents and
warrants that: 
 (a)    Organization, Authorization and Power. The Registered Holder is duly organized,
validly existing and in good standing under the laws of the jurisdiction of its organization and has the requisite power and authority to enter into and perform this Warrant and to acquire and hold the Warrant Stock. The execution, delivery and
performance of this Warrant by the Registered Holder and the consummation by it of the transactions contemplated hereby have been duly authorized by all necessary corporate action, and no further consent or authorization of the Registered Holder or
its board of directors, stockholders or other governing body is required. This Warrant is a valid and binding obligation of the Registered Holder, enforceable against the Registered Holder in accordance with its terms, except as such enforceability
may be limited by applicable bankruptcy, insolvency, reorganization, moratorium, liquidation, conservatorship, receivership or similar laws relating to, or affecting generally the enforcement of, creditor’s rights and remedies or by other
equitable principles of general application. 
 (b)    Acquisition of Warrant Stock for Own Account. The Warrant
Stock is being or will be acquired for investment for the Registered Holder’s own account, not as a nominee or agent, and not with a view to the public resale or distribution thereof within the meaning of the Securities Act, and the Registered
Holder has no present intent to sell, grant any participation in, or otherwise distribute the same. 

(c)    Sophistication and Suitability. The Registered Holder is knowledgeable, sophisticated and experienced in
making, and is qualified to make decisions with respect to, investments in securities presenting an investment decision like that involved in the acquisition of the Warrant Stock, including investments in securities issued by the Company and
investments in comparable companies, and has requested, received, reviewed and considered all information it deemed relevant in making an informed decision to acquire the Warrant Stock. The Registered Holder (a) has not been organized,
reorganized or recapitalized specifically for the purpose of investing in the Warrant Stock; (b) will not, directly or indirectly, offer, sell, pledge, transfer or otherwise dispose of (or solicit any offers to buy, purchase or otherwise
acquire to take a pledge of) any of the Warrant Stock except in compliance with the Securities Act and applicable state securities laws; (c) understands that the Warrant Stock is being offered and sold to it in reliance upon specific exemptions
from the registration requirements of the Securities Act and state securities laws, and that the Company is relying upon the truth and accuracy of, and the Registered Holder’s compliance with, the representations, warranties, agreements,
acknowledgments and understandings of the Registered Holder set forth herein in order to determine the availability of such exemptions and the eligibility of the Registered Holder to acquire the Warrant Stock;

  
 -7- 

 
(d) understands that its investment in the Warrant Stock involves a significant degree of risk, including a risk of total loss of the Registered Holder’s investment; and
(e) understands that no United States federal or state agency or any other government or governmental agency has passed upon or made any recommendation or endorsement of the Warrant Stock. 

(d)    Accredited Investor Status. The Registered Holder is an “accredited investor” within the meaning
of Regulation D promulgated under the Securities Act. 
 (e)    Private Placement. The Registered Holder
acknowledges and agrees that the Warrant Stock is being offered in a transaction not involving a public offering within the meaning of the Securities Act and that the Warrant Stock has not been registered under the Securities Act. The Registered
Holder acknowledges and agrees that the Warrant Stock may not be offered, resold, transferred, pledged or otherwise disposed of by the Registered Holder absent an effective registration statement under the Securities Act or an applicable exemption
from the registration requirements of the Securities Act, including Rule 144 promulgated thereunder. 
 (f)    No
Solicitation. At no time was the Registered Holder presented with or solicited by any publicly issued or circulated newspaper, mail, radio, television or other form of general advertising or solicitation in connection with the offer, sale and
purchase of the Warrant Stock. 
 (g)    Legends. The Registered Holder understands and agrees that the
certificates evidencing the Warrant Stock may bear legends substantially similar to those set forth below in addition to any other legend that may be required by applicable law, by the Company’s Amended and Restated Articles of Incorporation or
Bylaws, and by any agreement between the Company and the Registered Holder: 
 THESE SECURITIES HAVE NOT BEEN REGISTERED WITH THE SECURITIES
AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT
PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE
SECURITIES LAWS OR BLUE SKY LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE COMPANY. 
 The Warrant Stock is to be registered
in connection the transactions contemplated by the Merger Agreement and any lock-up agreement applicable to the Warrant Stock may be waived by the Company following the consummation of the transactions
contemplated by the Merger Agreement. 

  
 -8- 

 (h)    No Legal, Tax or Investment Advice. The Registered Holder
has reviewed with its own tax advisors the federal, state, local and foreign tax consequences of the acquisition of the Warrant Stock and the other transactions contemplated by this Warrant. The Registered Holder has relied solely on such advisors
and has not relied on any statements or representations of the Company, the Company’s counsel, or any of the Company’s agents regarding the federal, state, local and foreign tax consequences of the acquisition of the Warrant Stock or the
other transactions contemplated by this Warrant. The Registered Holder understands that it (and not the Company) will be responsible for its own tax liability that may arise as a result of this investment or the transactions contemplated by this
Warrant. 
 15.    Miscellaneous. 

(a)    Governing Law. The validity, interpretation, construction and performance of this Warrant, and
all acts and transactions pursuant hereto and the rights and obligations of the parties hereto shall be governed, construed and interpreted in accordance with the laws of the state of Delaware, without giving effect to principles of conflicts of
law. 
 (b)    Entire Agreement. This Warrant sets forth the entire agreement and understanding of
the parties relating to the subject matter herein and supersedes all prior or contemporaneous discussions, understandings and agreements, whether oral or written, between them relating to the subject matter hereof. 

(c)    Amendments and Waivers. No modification of or amendment to this Warrant, nor any waiver of any
rights under this Warrant, shall be effective unless in writing signed by the Company and the Registered Holder. No delay or failure to require performance of any provision of this Warrant shall constitute a waiver of that provision as to that or
any other instance. 
 (d)    Successors and Assigns. The terms and conditions of this Warrant
shall inure to the benefit of and be binding upon the respective successors and assigns of the parties. 

(e)    Notices. Any notice, demand or request required or permitted to be given under this Warrant
shall be in writing and shall be deemed sufficient when delivered personally or by overnight courier or sent by email, or 48 hours after being deposited in the U.S. mail as certified or registered mail with postage prepaid, addressed to the party to
be notified at such party’s address as set forth on the signature page, as subsequently modified by written notice, or if no address is specified on the signature page, at the most recent address set forth in the Company’s books and
records. 
 (f)    Severability. If one or more provisions of this Warrant are held to be
unenforceable under applicable law, the parties agree to renegotiate such provision in good faith. In the event that the parties cannot reach a mutually agreeable and enforceable replacement for such provision, then (a) such provision shall be
excluded from this Warrant, (b) the balance of this Warrant shall be interpreted as if such provision were so excluded and (c) the balance of this Warrant shall be enforceable in accordance with its terms. 

  
 -9- 

 (g)    Construction. This Warrant is the result of
negotiations between and has been reviewed by each of the parties hereto and their respective counsel, if any; accordingly, this Warrant shall be deemed to be the product of all of the parties hereto, and no ambiguity shall be construed in favor of
or against any one of the parties hereto. 
 (h)    Counterparts. This Warrant may be executed in
any number of counterparts, each of which shall be deemed an original, and all of which together shall constitute one and the same instrument. 

[Signature Page Follows] 

  
 -10- 

 IN WITNESS WHEREOF, the Company and the Registered Holder have executed this Warrant as of
the date first set forth above. 
  

			
	THE COMPANY:
	
	 KINETA, INC.

		
	 By:
	 	  

		 	(Signature)
	 Name:
	 	 Craig Philips

	 Title:
	 	 President

	  
 Address:

219 Terry Ave #300

	 Seattle, WA 98109

	 United States

  

	
	 ACCEPTED AND AGREED:

	
	THE REGISTERED HOLDER:
	
	  

(PRINT NAME)

	
	  

(Signature)

	
	 Address:

	
                   
                     

	
                   
                     

	
Email:                  
           

 SIGNATURE PAGE TO WARRANT FOR NON-VOTING COMMON STOCK 

OF KINETA, INC. 

 EXHIBIT A 

PURCHASE/EXERCISE FORM 
  

			
	To:    Kineta, Inc.	  	Dated:                                

 The undersigned, pursuant to the provisions set forth in the attached Warrant No.     , hereby irrevocably
elects to (a) purchase              shares of the capital stock covered by such Warrant and herewith makes payment of
$            , representing the full purchase price for such shares at the price per share provided for in such Warrant, or (b) exercise such Warrant for
             shares purchasable under the Warrant pursuant to the Net Issue Exercise provisions of Section 3(c) of such Warrant. 

The undersigned acknowledges that it has reviewed the representations and warranties of the Registered Holder set forth in Section 14 of
the Warrant and by its signature below hereby makes such representations and warranties to the Company. 
  

			
	ACKNOWLEDGED AND AGREED TO BY 
THE REGISTERED HOLDER:
	
	  

(Registered Holder)

		
	 By:
	 	  

		 	(Signature)
	 Name:
	 	  

	 Title:
	 	  

	
	
	 Address:

	
                   
                     

	
                   
                     

	
Email:                  
           

 EXHIBIT B 

ASSIGNMENT FORM 
 FOR
VALUE RECEIVED,                      hereby sells, assigns and transfers all of the rights of the undersigned under the attached Warrant with respect
to the number of shares of capital stock covered thereby set forth below, unto: 
  

					
	 Name of Assignee
	 	 Address/Facsimile Number
	 	 No. of Shares

		 		 	
		 		 	
		 		 	
		 		 	

  

			
	ACKNOWLEDGED AND AGREED TO BY 
THE REGISTERED HOLDER:
	
	  

(Registered Holder)

		
	 By:
	 	  

		 	(Signature)
	 Name:
	 	  

	 Title:
	 	  

	
	
	 Address:

	
                   
                     

	
                   
                     

	
Email:EX-10.4

 Exhibit 10.4 

YUMANITY THERAPEUTICS, INC. 

AMENDMENT NO. 2 TO REGISTRATION RIGHTS AGREEMENT 

This Amendment No. 2 to Registration Rights Agreement (this “Amendment”) is made as of December
            , 2022, by and among Yumanity Therapeutics, Inc., a Delaware corporation (the “Company”), and the undersigned Purchasers (as defined in the Agreement,
which is defined below). Capitalized terms used herein but not otherwise defined herein shall have the meanings given to them in the Agreement. 

RECITALS 
 WHEREAS,
the Company is party to that Agreement and Plan of Merger dated as of June 5, 2022 (as such may be amended from time to time, the “Merger Agreement”), by and among the Company, Yacht Merger Sub, Inc., a Washington corporation
and wholly owned subsidiary of the Company, and Kineta, Inc., a Washington corporation (“Kineta”), pursuant to which Kineta will become a wholly-owned subsidiary of the Company; 

WHEREAS, in connection with the Merger Agreement, the Company and certain of the Purchasers (each an “Original Purchaser”)
entered into (i) a Securities Purchase Agreement dated as of June 5, 2022, as amended by the Amendment No. 1 to Securities Purchase Agreement dated as of October 24, 2022 (as such may be further amended from time to time, the
“PIPE Agreement”), pursuant to which the Company agreed to sell and issue to each Purchaser certain shares of the Company’s common stock, par value $0.001 per share and (ii) a Registration Rights Agreement dated as of
June 5, 2022 as amended by the Amendment No. 1 to Registration Rights Agreement dated as of October 24, 2022 (as such may be further amended from time to time, the “Agreement”), pursuant to which the Company agreed to
provide certain registration rights with respect to the Registrable Securities under the Securities Act and the rules and regulations promulgated thereunder, and applicable state securities laws; 

WHEREAS, concurrently with the execution and delivery of this Amendment, the Company and the undersigned Purchasers are entering into an
Amendment No. 2 to the PIPE Agreement (the “PIPE Amendment”); 
 WHEREAS, certain parties hereto (each a “New
Purchaser”) (i) are entering into the PIPE Amendment to become parties to the PIPE Agreement as “Purchasers” (as defined therein) thereunder and (ii) desire to enter into the Agreement and are executing and delivering this
Amendment to acknowledge the terms hereof and to become parties to the Agreement as Purchasers thereunder; and 
 WHEREAS, the Company and
the undersigned Purchasers, which include all of the Original Purchasers, now wish to amend the Agreement as set forth herein; 

 AGREEMENT 

In consideration of the mutual promises, covenants and conditions hereinafter set forth, the parties hereto mutually agree as follows: 

1.      Amendments to Registration Rights Agreement.  

a.    Preamble to the Agreement is hereby amended and restated in its entirety to read as follows: 

“THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made and entered into as of June 5, 2022, by
and among Yumanity Therapeutics, Inc., a Delaware corporation (the “Company”), and the purchasers set forth on Schedule 1 hereto (each, a “Purchaser”, and collectively, the
“Purchasers”), and shall become effective, subject to Section 8.1 below, as of the First Tranche Closing (as defined in the Purchase Agreement, defined below).” 

b.    Recital C of the Agreement is hereby amended and restated in its entirety to read as follows: 

“In connection with the Merger and pursuant to the Securities Purchase Agreement, by and among the Company and the Purchasers, dated as of
June 5, 2022 (as such may be amended and/or restated from time to time, the “Purchase Agreement”), the Company has agreed, upon the terms and conditions stated in the Purchase Agreement, to issue and sell to the Purchasers on
the applicable Closing Date shares of Common Stock (the “Shares”).” 
 c.    The
definition of “Closing Date” in Article I of the Agreement is hereby amended and restated in its entirety to read as follows: 

“Closing Date” means the applicable date of the closing of the acquisition and issuance of the Shares pursuant to the Purchase
Agreement, which may be the First Tranche Closing Date (as defined in the Purchase Agreement) or the Second Tranche Closing Date (as defined in the Purchase Agreement).” 

d.    Section 2.1 is hereby amended such that the fourth sentence thereof is amended and restated in its
entirety to read as follows: 
 “The Company shall use commercially reasonable efforts to cause the Registration Statement filed by it
to be declared effective under the Securities Act as promptly as practicable after the filing thereof but in any event on or prior to the Effectiveness Deadline, and, subject to Section 4.1(m) hereof, to keep such Registration Statement
continuously effective under the Securities Act until the earlier of (i) such date as all Registrable Securities covered by such Registration Statement have ceased to be Registrable Securities or (ii) the date that is two (2) years
following the applicable Closing Date (as defined in the Purchase Agreement) (the “Effectiveness Period”). For the avoidance of doubt, the Company may be required to file more than one Registration Statement pursuant to this
Section 2.1 to register resale of both the First Tranche Shares and the Second Tranche Shares (as defined in the Purchase Agreement).” 

  
 2 

 e.    Section 8.5 of the Agreement is hereby amended
such that, following the First Tranche Closing (as defined in the Purchase Agreement), copies of notices or other communications or deliveries under the Agreement delivered to the Company shall also be sent to Orrick, Herrington & Sutcliffe
LLP. 
 f.    Section 8.1 of the Agreement is hereby amended and restated in its entirety to read as
follows: 
 “Effectiveness. The Company’s obligations hereunder shall be conditioned upon the occurrence of the First
Tranche Closing under the Purchase Agreement, and this Agreement shall not be effective until the First Tranche Closing. If the Purchase Agreement shall be terminated prior to the First Tranche Closing, then this Agreement shall be void and of no
further force or effect (and no party hereto shall have any rights or obligations with respect to this Agreement).” 

g.    Schedule 1 to the Agreement is hereby amended and restated in its entirety to read as set
forth on Exhibit A attached hereto. 
 h.    Upon the effectiveness of this Amendment,
(i) Genetox, Inc. (“Genetox”), an Original Purchaser, shall be relieved of all obligations to perform under the Agreement (except for purposes of this Amendment) and shall no longer be a party to the Agreement (except for
purposes of this Amendment), and all rights of Genetox under the Agreement (except for purposes of this Amendment) shall terminate and (ii) there shall be no liability under the Agreement on the part of Genetox, on the one hand, nor any other
party to this Amendment, on the other hand. 
 i.    Effective upon the execution and delivery of this
Amendment by a New Purchaser, each such New Purchaser shall be deemed a party to the Agreement for all purposes as a “Purchaser” thereunder. The Company may update Schedule 1 to the Agreement to reflect the addition of each such New
Purchaser without the approval of any other party to the Agreement. 
 2.      Defined Terms;
Effectiveness and Effect of Amendment. Upon the effectiveness of this Amendment, each reference in the Agreement to “this Agreement,” “hereunder,” “hereof,” “herein,” or words of like import
shall mean and be a reference to the Agreement as amended hereby, and each reference to the Agreement in any other document, instrument or agreement executed or delivered in connection with the Agreement shall mean and be a reference to the
Agreement as amended hereby. All provisions and terms of the Agreement not specifically altered by this Amendment shall remain in full force and effect. 

3.      Governing Law. The validity, interpretation, construction and performance of this
Amendment, and all acts and transactions pursuant hereto and the rights and obligations of the Company and the Purchasers shall be governed, construed and interpreted in accordance with the laws of the State of Delaware, without giving effect to
principles of conflicts of law. 

  
 3 

 4.      Counterparts. This Amendment may
be executed in one or more counterparts, each of which shall be deemed to be an original but all of such together will constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including .pdf or any
electronic signature complying with the U.S. Federal ESIGN Act of 2000, e.g. www.docusign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all
purposes. 
 [Signature Pages Follow] 

  
 4 

 The parties have executed this Amendment No. 2 to Registration Rights Agreement as of
the date first written above. 
  

			
	THE COMPANY:
	
	YUMANITY THERAPEUTICS, INC.
		
	By:	 	  

		 	(Signature)
		
	Name:	 	  

	Title:	 	  

  

  

AMENDMENT NO. 2 TO REGISTRATION RIGHTS
AGREEMENT 

 The parties have executed this Amendment No. 2 to Registration Rights Agreement as of
the date first written above. 
  

			
	PURCHASERS:
	
	[                        ]
		
	By:	 	  

		 	(Signature)
		
	Name:	 	  

	Title:	 	  

	
	[                        ]
		
	By:	 	  

		 	(Signature)
		
	Name:	 	  

	Title:	 	  

  

  

AMENDMENT NO. 2 TO REGISTRATION RIGHTS
AGREEMENT

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00351-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00351-of-00352.parquet"}]]